Effect of advanced oxidation protein products on the proliferation and osteogenic differentiation of rat mesenchymal stem cells

International Journal of Molecular Medicine

Volumn 32, Issue 2, 2013, Pages 485-491

  Sun, Nan ^a   Yang, Li ^a   Li, Yingbin ^b   Zhang, Hua ^a   Chen, Hong ^a   Liu, Duan ^a   Li, Qingnan ^b   Cai, Dehong ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Advanced oxidation protein products; Differentiation; Proliferation; Reactive oxygen species; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; DICHLORODIHYDROFLUORESCEIN DIACETATE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOBLAST; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAGE; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ADVANCED OXIDATION PROTEIN PRODUCTS; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SEPARATION; GENE EXPRESSION REGULATION; MALE; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; RATS; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC;

EID: 84879376126     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1402     Document Type: Article

References (37)

1. Wongdee K and Charoenphandhu N: Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms. World J Diabetes 2: 41-48, 2011.
2. Cervellati C, Bonaccorsi G, Cremonini E, Bergamini CM, Patella A, Castaldini C, Ferrazzini S, Capatti A, Picarelli V, Pansini FS and Massari L: Bone mass density selectively correlates with serum markers of oxidative damage in post-menopausal women. Clin Chem Lab Med 51: 333-338, 2013.
3. Fatokun AA, Stone TW and Smith RA: Responses of differentiated MC3T3-E1 osteoblast-like cells to reactive oxygen species. Eur J Pharmacol 587: 35-41, 2008.
4. Sheweita SA and Khoshhal KI: Calcium metabolism and oxidative stress in bone fractures: Role of antioxidants. Curr Drug Metab 8: 519-525, 2007. (Pubitemid 47603416)
5. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, NguyenKhoa T, Nguyen AT, Zingraff J, Jungers P and Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-1313, 1996. (Pubitemid 26166404)
6. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drueke T and Descamps-Latscha B: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161: 2524-2532, 1998. (Pubitemid 28397070)
7. Guo ZJ, Niu HX, Hou FF, Zhang L, Fu N, Nagai R, Lu X, Chen BH, Shan YX, Tian JW, Nagaraj RH, Xie D and Zhang X: Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 10: 1699-1712, 2008.
8. Piwowar A: Advanced oxidation protein products. Part I. Mechanism of the formation, characteristics and property. Pol Merkur Lekarski 28: 166-169, 2010 (In Polish).
9. Piwowar A, Knapik-Kordecka M and Warwas M: AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res Clin Pract 77: 188-192, 2007. (Pubitemid 46670416)
10. Cumaoglu A, Cevik C, Rackova L, Ari N and Karasu C: Effects of antioxidant stobadine on protein carbonylation, advanced oxidation protein products and reductive capacity of liver in streptozotocin-diabetic rats: Role of oxidative/nitrosative stress. BioFactors 30: 171-178, 2007. (Pubitemid 352038452)
11. Krzystek-Korpacka M, Neubauer K, Berdowska I, Boehm D, Zielinski B, Petryszyn P, Terlecki G, Paradowski L and Gamian A: Enhanced formation of advanced oxidation protein products in IBD. Inflamm Bowel Dis 14: 794-802, 2008. (Pubitemid 351898064)
12. Kaneda H, Taguchi J, Ogasawara K, Aizawa T and Ohno M: Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 162: 221-225, 2002. (Pubitemid 34327362)
13. Collet C, Schiltz C, Geoffroy V, Maroteaux L, Launay JM and de Vernejoul MC: The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J 22: 418-427, 2008. (Pubitemid 351225578)
14. Zhang YB, Zhong ZM, Hou G, Jiang H and Chen JT: Involvement of oxidative stress in age-related bone loss. J Surg Res 169: E37-e42, 2011.
15. Choi EM and Kim YH: Hesperetin attenuates the highly reducing sugar-triggered inhibition of osteoblast differentiation. Cell Biol Toxicol 24: 225-231, 2008. (Pubitemid 351579709)
16. Lee KH and Choi EM: Myricetin, a naturally occurring flavonoid, prevents 2-deoxy-D-ribose induced dysfunction and oxidative damage in osteoblastic MC3T3-E1 cells. Eur J Pharmacol 591: 1-6, 2008.
17. Zhong ZM, Bai L and Chen JT: Advanced oxidation protein products inhibit proliferation and differentiation of rat osteoblast-like cells via NF-kappaB pathway. Cell Physiol Biochem 24: 105-114, 2009.
18. Rodan GA and Martin TJ: Therapeutic approaches to bone diseases. Science 289: 1508-1514, 2000.
19. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147, 1999. (Pubitemid 29282067)
20. Long MW: Osteogenesis and bone-marrow-derived cells. Blood Cells Mol Dis 27: 677-690, 2001. (Pubitemid 32757064)
21. Dalle Carbonare L, Valenti MT, Zanatta M, Donatelli L and Lo Cascio V: Circulating mesenchymal stem cells with abnormal osteogenic differentiation in patients with osteoporosis. Arthritis Rheum 60: 3356-3365, 2009.
22. Benisch P, Schilling T, Klein-Hitpass L, Frey SP, Seefried L, Raaijmakers N, Krug M, Regensburger M, Zeck S, Schinke T, Amling M, Ebert R and Jakob F: The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors. PloS One 7: E45142, 2012.
23. Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T, Kojiro M and Nagata K: Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 20: 1647-1658, 2005. (Pubitemid 41243553)
24. Farley JR and Jorch UM: Differential effects of phospholipids on skeletal alkaline phosphatase activity in extracts, in situ and in circulation. Arch Biochem Biophys 221: 477-488, 1983. (Pubitemid 13135509)
25. Harada S and Rodan GA: Control of osteoblast function and regulation of bone mass. Nature 423: 349-355, 2003. (Pubitemid 40852710)
26. Deng YQ, Fu Y, Su XP and Tang ZY: Biologic effects of advanced oxidative protein products on the human gingival fibroblasts. Zhonghua Kou Qiang Yi Xue Za Zhi 44: 270-273, 2009 (In Chinese).
27. Ouyang P, Liu S, Bei W, Lai W, Hou F and Xu A: Effects of flavone from leaves of Diospyros kaki on adventitial fibroblasts proliferation by advanced oxidation protein products in vitro. Zhong Yao Cai 27: 186-188, 2004 (In Chinese).
28. Siggelkow H, Rebenstorff K, Kurre W, Niedhart C, Engel I, Schulz H, Atkinson MJ and Hufner M: Development of the osteoblast phenotype in primary human osteoblasts in culture: Comparison with rat calvarial cells in osteoblast differentiation. J Cell Biochem 75: 22-35, 1999. (Pubitemid 29402541)
29. Beck GR Jr, Sullivan EC, Moran E and Zerler B: Relationship between alkaline phosphatase levels, osteopontin expression, and mineralization in differentiating MC3T3-E1 osteoblasts. J Cell Biochem 68: 269-280, 1998. (Pubitemid 28028084)
30. Bai XC, Lu D, Bai J, Zheng H, Ke ZY, Li XM and Luo SQ: Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun 314: 197-207, 2004. (Pubitemid 38058389)
31. Lee NK, Choi YG, Baik JY, Han SY, Jeong DW, Bae YS, Kim N and Lee SY: A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106: 852-859, 2005. (Pubitemid 41076424)
32. Barbagallo I, Vanella A, Peterson SJ, Kim DH, Tibullo D, Giallongo C, Vanella L, Parrinello N, Palumbo GA, Di Raimondo F, Abraham NG and Asprinio D: Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. J Bone Mineral Metab 28: 276-288, 2010.
33. Yan SF, Ramasamy R and Schmidt AM: The RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature. Circ Res 106: 842-853, 2010.
34. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM and Wautier JL: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280: E685-E694, 2001.
35. Yamagishi S: Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets 12: 2096-2102, 2011.
36. Li G, Xu J and Li Z: Receptor for advanced glycation end products inhibits proliferation in osteoblast through suppression of Wnt, PI3K and ERK signaling. Biochem Biophys Res Commun 423: 684-689, 2012.
37. Ding KH, Wang ZZ, Hamrick MW, Deng ZB, Zhou L, Kang B, Yan SL, She JX, Stern DM, Isales CM and Mi QS: Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun 340: 1091-1097, 2006. (Pubitemid 43083390)